What Researchers Did
Taiwanese researchers compared visual outcomes in 99 patients with central retinal artery occlusion (CRAO — a stroke of the eye) treated with conservative care, intra-arterial blood clot-dissolving therapy, or HBOT — notably in patients who were already past the standard treatment window (most treated days after symptom onset).
What They Found
Despite the HBOT group having more severe cases and a median 6-day delay to treatment (vs. 4 days for conservative care), 51.3% of HBOT patients achieved significant vision improvement at 6 months, compared to only 24.0% in the conservative care group (p < 0.05). This improvement was maintained at 12 months and at the final exam. The clot-dissolving therapy group showed a non-significant trend toward improvement over conservative care.
What This Means for Canadian Patients
For Canadians who experience sudden vision loss from a retinal artery occlusion and do not receive treatment within the first 24 hours, HBOT may still offer meaningful vision recovery even days later — a finding not shown in previous research. Patients should seek HBOT consultation even if they believe they have missed the treatment window.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This was a retrospective study where patients were not randomly assigned to treatments, and the HBOT group had more severe cases at baseline, which makes the positive results even more noteworthy but also harder to interpret without randomization.